參考文獻 |
1. Cortes-Funes, H.; Coronado, C., Role of anthracyclines in the era of targeted therapy. Cardiovascular toxicology 2007, 7 (2), 56-60.
2. Zhao, Q.; Han, B.; Wang, Z.; Gao, C.; Peng, C.; Shen, J., Hollow chitosan-alginate multilayer microcapsules as drug delivery vehicle: doxorubicin loading and in vitro and in vivo studies. Nanomedicine : nanotechnology, biology, and medicine 2007, 3 (1), 63-74.
3. Zhu, L.; Kate, P.; Torchilin, V. P., Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS nano 2012, 6 (4), 3491-8.
4. Liang, J. F.; Yang, V. C., Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorganic & medicinal chemistry letters 2005, 15 (22), 5071-5.
5. Frenkel, V.; Etherington, A.; Greene, M.; Quijano, J.; Xie, J.; Hunter, F.; Dromi, S.; Li, K. C., Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Academic radiology 2006, 13 (4), 469-479.
6. Sapra, P.; Allen, T. M., Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer research 2002, 62 (24), 7190-4.
7. Shi, N. Q.; Gao, W.; Xiang, B.; Qi, X. R., Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. International journal of nanomedicine 2012, 7, 1613-21.
8. Langer, R., Drug delivery and targeting. Nature 1998, 392 (6679 Suppl), 5-10.
9. Sneader, W., The discovery of aspirin: a reappraisal. BMJ 2000, 321 (7276), 1591-4.
10. Frederick, C. A.; Williams, L. D.; Ughetto, G.; van der Marel, G. A.; van Boom, J. H.; Rich, A.; Wang, A. H., Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29 (10), 2538-49.
11. González, I. D.; Saez, R. S.; Rodilla, E. M.; Yges, E.; Toledano, F., Hypersensitivity reactions to chemotherapy drugs. Alergol Immunol Clin 2000, 15, 161-181.
12. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D., The future of peptide-based drugs. Chemical biology & drug design 2013, 81 (1), 136-47.
13. Quattrocchi, E.; Kourlas, H., Teriparatide: a review. Clinical therapeutics 2004, 26 (6), 841-54.
14. Kjeldsen, T., Yeast secretory expression of insulin precursors. Applied microbiology and biotechnology 2000, 54 (3), 277-86.
15. Couch, R. B., Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26 Suppl 4, D5-9.
16. Neumann, G.; Fujii, K.; Kino, Y.; Kawaoka, Y., An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proceedings of the National Academy of Sciences of the United States of America 2005, 102 (46), 16825-16829.
17. In Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma, J Clin Oncol (Meeting Abstracts), 2006; p 1566.
18. Hughes, G. A., Nanostructure-mediated drug delivery. Disease-a-month : DM 2005, 51 (6), 342-61.
19. Liong, M.; Lu, J.; Kovochich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; Tamanoi, F.; Zink, J. I., Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS nano 2008, 2 (5), 889-96.
20. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P. W.; Langer, R.; Farokhzad, O. C., Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano letters 2007, 7 (10), 3065-70.
21. Cheng, Y.; A, C. S.; Meyers, J. D.; Panagopoulos, I.; Fei, B.; Burda, C., Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. Journal of the American Chemical Society 2008, 130 (32), 10643-7.
22. Namazi, H.; Adeli, M., Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents. Biomaterials 2005, 26 (10), 1175-83.
23. Pasut, G.; Veronese, F., Polymer–drug conjugation, recent achievements and general strategies. Progress in Polymer Science 2007, 32 (8), 933-961.
24. Khandare, J.; Minko, T., Polymer–drug conjugates: progress in polymeric prodrugs. Progress in Polymer Science 2006, 31 (4), 359-397.
25. Bangham, A. D.; Horne, R. W., Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope. Journal of molecular biology 1964, 8, 660-8.
26. Torchilin, V. P., Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery 2005, 4 (2), 145-160.
27. Greish, K., Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010, 624, 25-37.
28. Maruyama, K., Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Advanced drug delivery reviews 2011, 63 (3), 161-9.
29. Juliano, R., Liposomes and the reticuloendothelial system: interactions of liposomes with macrophages and behavior of liposomes in vivo. In Targeting of drugs, Springer: 1982; pp 285-300.
30. Patankar, N.; Waterhouse, D., Nano-particulate Drug Delivery Systems for Camptothecins. Cancer Therapy 2012, 8, 90-104.
31. Hancock, R. E., Peptide antibiotics. Lancet 1997, 349 (9049), 418-22.
32. Zasloff, M., Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proceedings of the National Academy of Sciences of the United States of America 1987, 84 (15), 5449-53.
33. Frankel, A. D.; Pabo, C. O., Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55 (6), 1189-93.
34. Derossi, D.; Joliot, A. H.; Chassaing, G.; Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes. The Journal of biological chemistry 1994, 269 (14), 10444-50.
35. Powers, J.-P. S.; Hancock, R. E., The relationship between peptide structure and antibacterial activity. Peptides 2003, 24 (11), 1681-1691.
36. Rozek, A.; Friedrich, C. L.; Hancock, R. E., Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. Biochemistry 2000, 39 (51), 15765-74.
37. Tsai, C. W.; Hsu, N. Y.; Wang, C. H.; Lu, C. Y.; Chang, Y.; Tsai, H. H.; Ruaan, R. C., Coupling molecular dynamics simulations with experiments for the rational design of indolicidin-analogous antimicrobial peptides. Journal of molecular biology 2009, 392 (3), 837-54.
38. Storm, G., Liposomes as delivery system for doxorubicin in cancer chemotherapy. Pharmaceutisch weekblad. Scientific edition 1988, 10 (6), 288-90.
39. Janes, K. A.; Fresneau, M. P.; Marazuela, A.; Fabra, A.; Alonso, M. J., Chitosan nanoparticles as delivery systems for doxorubicin. Journal of controlled release : official journal of the Controlled Release Society 2001, 73 (2-3), 255-67.
40. Kovar, M.; Strohalm, J.; Etrych, T.; Ulbrich, K.; Rihova, B., Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjugate chemistry 2002, 13 (2), 206-15.
41. Ma, Y.; Manolache, S.; Denes, F. S.; Thamm, D. H.; Kurzman, I. D.; Vail, D. M., Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. Journal of biomaterials science. Polymer edition 2004, 15 (8), 1033-49.
42. Bae, M.; Cho, S.; Song, J.; Lee, G. Y.; Kim, K.; Yang, J.; Cho, K.; Kim, S. Y.; Byun, Y., Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis. Drugs under experimental and clinical research 2003, 29 (1), 15-23.
43. Working, P. K.; Dayan, A. D., Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Human & experimental toxicology 1996, 15 (9), 751-85.
44. Gabizon, A. A., Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer investigation 2001, 19 (4), 424-36.
45. Terada, T.; Iwai, M.; Kawakami, S.; Yamashita, F.; Hashida, M., Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. Journal of controlled release : official journal of the Controlled Release Society 2006, 111 (3), 333-42.
46. Chung, D. E.; Kratz, F., Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorganic & medicinal chemistry letters 2006, 16 (19), 5157-63.
47. Veronese, F. M.; Pasut, G., PEGylation, successful approach to drug delivery. Drug discovery today 2005, 10 (21), 1451-8.
48. Katayama, S.; Hirose, H.; Takayama, K.; Nakase, I.; Futaki, S., Acylation of octaarginine: Implication to the use of intracellular delivery vectors. Journal of controlled release : official journal of the Controlled Release Society 2011, 149 (1), 29-35.
49. Turk, B. E.; Huang, L. L.; Piro, E. T.; Cantley, L. C., Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature biotechnology 2001, 19 (7), 661-7. |